Peter Hein

Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands.

Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands.

Part of Abbott Laboratories, Abbott Healthcare Products BV is a Dutch company that manufactures and distributes pharmaceuticals. The company is based in Weesp, Netherlands.

deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium.

Part of DSM-Firmenich AG, DSM Biologics Holding, Inc. is a Canadian company that manufactures biological and pharmaceutical products. The private company is based in Montréal, Canada. The company was founded by Jos van Weperen. DSM Biologics Holding was acquired by DSM Pharmaceuticals, Inc., a subsidiary of DSM-Firmenich AG from Province of Québec on July 13, 2005.

PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

Isobionics BV operates as a holding company, which produces flavor and fragrance ingredients. The firm manufactures and supplies natural chemical substances such as Valencene, Nootkatone, and Beta-Elemene. The company was founded by Toine Janssen in 2008 and is headquartered in Geleen, the Netherlands.

SP Sveriges Tekniska Forskningsinstitut AB operates as a international research institute. Its business areas include energy, information and communications technology, life science, risk, safety and security, the built environment and transportation. The company was founded in 1920 and is headquartered in Borås, Sweden.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

Ceradis BV develops and markets environmental solutions for plant nutrition, crop protection, and formulation services. It focuses on the use of biological formulation additives and the development of biofungicides based on macro-organisms or natural products. The company was founded by Wim M. van der Krieken in 2005 and is headquartered in Wageningen, the Netherlands.

DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands.

Exponential BV is a Dutch company that provides management and business consulting services. The private company is based in Capelle aan de IJssel, Netherlands. The CEO of the company is Dharminder S. Chahal.

Quorics BV develops novel therapeutics and early diagnostic tests for cardiovascular diseases. The company was founded by Dharminder S. Chahal in 2012 and is headquartered in Rotterdam, the Netherlands.

VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands.

SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands.

Swanbridge Capital Management is a venture capital firm, headquartered in Netherland. The frim founded in 2016 by Van Herk Investments, the Erasmus Medical Center and the City of Rotterdam.

DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020.

Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.